NKX019 for lupus kidney disease or membranous nephropathy
Treatments studied
Part of Immune system & allergy, Kidney & urinary, Skin, Women’s health & pregnancy clinical trials.
This trial tests an experimental cell therapy called NKX019 for people with active lupus nephritis (a type of kidney inflammation from lupus) or primary membranous nephropathy (another kidney condition) that hasn't gotten better after standard treatments. It may help if you have tried at least two treatments for lupus kidney disease or one for membranous nephropathy and still have active kidney disease.
Summary written for real people, not researchers, by Clin2.
Who can take part
- You are between 18 and 75 years old.
- You have active lupus nephritis (Class III or IV) or primary membranous nephropathy confirmed by a kidney biopsy within the last 6 months.
- For lupus nephritis: you have had at least two prior treatments for kidney lupus and still have active disease (high protein in urine).
- For membranous nephropathy: you have had at least one prior treatment and still have active disease (very high protein in urine).
- Your kidney function is not too low (eGFR above 45 ml/min) and you do not need dialysis.
- You have not had a previous organ or stem cell transplant, and have no active infections or major heart/lung/liver problems.
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This Phase 2 study tests whether LNP023 can improve outcomes and safety in people with active lupus nephritis (lupus-related kidney inflammation), class III or IV. It may help by targeting the ongoing immune activity that is damaging the kidneys.
This trial tests a new treatment called CRC01, made from your own cells, for people with severe lupus that hasn't improved with standard medications. The goal is to see if it can safely control the disease and reduce symptoms.
This trial tests a new drug called SIM0278 for people with active lupus nephritis (kidney inflammation caused by lupus). It aims to see if adding this drug to standard treatment is safe and helpful for controlling the disease.
This trial tests whether adding the drug obinutuzumab to standard therapy (mycophenolate and steroids) helps control lupus-related kidney inflammation better than standard therapy alone. It might reduce kidney damage and improve outcomes for people with active lupus nephritis.
This trial tests a new cell therapy (RY_SW01) for people with active lupus nephritis (kidney inflammation caused by lupus) who haven't responded well to standard treatments. It aims to see if the therapy can help control the disease.
This study tests whether adding LUPKYNIS (a drug that protects the kidney) to one of three immune-system medications helps people with lupus nephritis (lupus affecting the kidneys). The goal is to reduce protein in urine and protect kidney function.
Hear when a new Lupus Nephritis trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.